Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics

Two anti-amyloid monoclonal antibodies (MABs)—lecanemab (Leqembi(®)) and aducanumab (Aduhelm(®))—have been approved in the USA for the treatment of Alzheimer's disease (AD). Anti-amyloid monoclonal antibodies are the first disease-modifying therapies for AD that achieve slowing of clinical decl...

Descripción completa

Detalles Bibliográficos
Autor principal: Cummings, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195708/
https://www.ncbi.nlm.nih.gov/pubmed/37060386
http://dx.doi.org/10.1007/s40265-023-01858-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195708/
https://www.ncbi.nlm.nih.gov/pubmed/37060386
http://dx.doi.org/10.1007/s40265-023-01858-9

Ejemplares similares